SESSION TITLE: PAH
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Sunday, October 23, 2016 at 01:30 PM - 03:00 PM
PURPOSE: Riociguat showed sustained efficacy in patients with PAH in the PATENT-2 study. We compared treatment-naïve and pretreated patients from the final data cut of PATENT-2.
METHODS: Patients with PAH who were treatment-naïve or pretreated with endothelin receptor antagonists (ERAs) or prostanoids entered PATENT-2 after completing PATENT-1 without ongoing riociguat-related SAEs. All patients received riociguat individually adjusted up to a maximum of 2.5 mg tid. Primary endpoints were safety and tolerability; secondary endpoints included 6-minute walking distance (6MWD), WHO functional class (FC), survival, and clinical worsening-free survival.